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Background: Nowadays, many cytotoxic anticancer drugs exhibit low solubility and poor tumor 
selectivity, which means that the drug formulation is very important. For example, in the case 
of paclitaxel (PTX), Cremophor EL® (BASF, Ludwigshafen, Germany) needs to be used as a 
solubilizer in its clinical formulation (Taxol®, Bristol-Myers Squibb, New York, NY), although 
it can cause serious side effects. Nanomicellar systems are promising carriers to resolve the 
above problems, and the polymer chosen is the key element.
Methods: In this study, a novel amphiphilic chitosan/vitamin E succinate (CS-VES) copolymer 
was successfully synthesized for self-assembling polymeric micelles. Proton nuclear magnetic 
resonance spectroscopy and infrared were used to characterize the molecular structure of the 
copolymer. The PTX-loaded CS-VES polymeric micelles (PTX-micelles) were characterized by 
dynamic light scattering, transmission electron microscopy, X-ray diffraction, and differential 
scanning calorimetry.
Results: The critical micelle concentration of CS-VES was about 12.6 µg/mL, with the degree 
of amino group substitution being 20.4%. PTX-micelles were prepared by a nanoprecipitation/
dispersion technique without any surfactant being involved. PTX-micelles exhibited a drug load-
ing as high as 21.37% and an encapsulation efficiency of 81.12%, with a particle size ranging 
from 326.3 to 380.8 nm and a zeta potential of +20 mV . In vitro release study showed a near 
zero-order sustained release, with 51.06%, 50.88%, and 44.35% of the PTX in the micelles being 
released up to 168 hours at three drug loadings of 7.52%, 14.09%, and 21.37%, respectively. 
The cellular uptake experiments, conducted by confocal laser scanning microscopy, showed 
an enhanced cellular uptake efficiency of the CS-VES micelles in MCF-7 cells compared with 
Taxol. The PTX-micelles exhibited a comparable but delayed cytotoxic effect compared with 
Taxol against MCF-7 cells, due to the sustained-release characteristics of the nanomicelles. 
More interestingly, blank nanomicelles based on CS-VES copolymer demonstrated significant 
cytotoxicity against MCF-7 cells.
Conclusion: The supramolecular micellar aggregates based on CS-VES copolymer is a promis-
ing nanocarrier and efficacy enhancer when used as an anticancer drug-delivery system.
Keywords: nanomicelles, cellular uptake, cytotoxicity
Introduction
Paclitaxel (PTX), a natural hydrophobic diterpenoid extracted from the bark of the 
Pacific yew, is a microtubule stabilizer used in cancer chemotherapy. PTX is widely 
used for the treatment of various solid tumors, including non-small cell lung, ovarian, 
breast, and prostate cancers.1–3 However, its clinical application has been severely 
limited by its poor aqueous solubility, about 1 µg/mL in water. So, the commercial 
PTX formulation (Taxol®, Bristol-Myers Squibb, New York, NY) was prepared with International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the aid of Cremophor EL® (BASF, Ludwigshafen, Germany) 
and absolute alcohol (50:50, v/v). However, severe toxic side 
effects can be caused by the use of Cremophor EL, such as 
hypersensitivity, neurotoxicity, and nephrotoxicity, and thus, 
patients require appropriate premedication.
In recent years, significant progress has been made 
in the development of novel PTX delivery systems, such 
as liposomes,4 emulsions,5,6 hydrogels,7 and polymeric 
micelles.8–12 Notable among these delivery systems are 
polymeric micelles because of their outstanding advantages, 
including the self-assembly of core-shell micelles in an aque-
ous environment, a smaller size and uniform size distribu-
tion, prolonged circulation time in the bloodstream, passive 
accumulation in solid tumors achieved by permeability and 
a retention effect, and easy surface functionalization with 
many targeting receptors (eg, folic acid, transferrin, and tras-
tuzumab) for improved intracellular tumor exposure.13–17
A range of natural or synthetic polymers have been 
used to develop polymeric micellar delivery nanosystems. 
  Chitosan, a polysaccharide derived from chitin by incomplete 
or complete deacetylation, is a promising choice.18,19 Most 
importantly, it is an alkalescent polysaccharide found in 
nature, and so it is readily available, with good biodegrad-
ability and biocompatibility, and no apparent toxicity during 
long-term therapy. Secondly, nanomicelles formed by chi-
tosan derivatives generally carry a positive charge on their 
surface, which contributes to the bioadhesive ability of the 
formulation and gene delivery by forming complexes with 
negatively charged deoxyribonucleic acid (DNA).20 Thirdly, 
it possesses good amenability to functional surface modifi-
cation (eg, folic acid21 and polyethylene glycol22) due to the 
high number of available hydroxyl and amino groups on 
the surface. In the past decade, polymeric micelles based on 
chitosan have been developed rapidly, and much progress has 
been made. For example, the amphiphilic N-octyl-O-sulfate 
chitosan was synthesized, and improves the solubility of PTX 
up to 2.6 mg/mL, 1000 times higher than in water.23 In addi-
tion, the antitumor efficiency of N-octyl-O-sulfate chitosan is 
similar to Taxol but produces less toxicity.24 Another study 
reports that stearic acid (SA) can be grafted with chitosan 
oligosaccharide (CSO).25 This new CSO/SA copolymer 
can significantly condense the plasmid DNA and exhibits 
a marked transfection enhancement compared with CSO. 
Hydrophobically modified glycol chitosan nanoparticles with 
cholanic acid as the hydrophobic core have been prepared 
to encapsulate the anticancer drug docetaxel (DTX).26 DTX 
nanoparticles are stable and well dispersed under physi-
ological conditions, and they exhibit a better tumor-targeting 
ability compared with DTX solution and increase the survival 
rate in A-549 lung cancer cell-bearing mice.
In recent years, vitamin E succinate (RRR-α-tocopheryl 
succinate, VES), an esterified redox-silent analog of vitamin E, 
has had more attention than other compounds in the vitamin E 
family. It can induce apoptosis of malignant cells without 
any toxicity to normal cells.27,28 Great efforts have been 
made to explain the selective apoptosis mechanism of VES, 
and it has been found that VES can trigger rapid production 
of reactive oxygen species,29 and induce caspase-dependent 
apoptosis by inhibiting the combination of Bcl-2 and Bcl-xl 
with Bcl-2 homology 3 (BH3).30 In combination, VES is a 
potent inducer of apoptosis in cancer cells, rather than in 
normal cells, and thus, is a promising efficacy enhancer in 
cancer chemotherapy.
With regards to the hydrophobicity and enhanced anti-
cancer efficacy of VES, the authors of this paper designed 
a new chitosan-VES (CS-VES) copolymer for the first 
time, in which VES was the hydrophobic portion and 
chitosan was the hydrophilic backbone (Figure 1A). The 
amphiphilic CS-VES copolymer self-assembled nanomi-
celles in aqueous conditions and efficiently encapsulated 
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the hydrophobic anticancer drug, PTX, used in this study 
(Figure 1B). Firstly, and most importantly, blank nanomi-
celles formed by CS-VES copolymer exhibited significant 
cytotoxicity against MCF-7 cells but had no apparent 
effect on hemolysis and erythrocyte agglutination at the 
highest concentration of 2 mg/mL. These results suggest 
that supramolecular micellar nanoaggregates based on the 
novel CS-VES copolymer are a promising nanocarrier for 
anticancer drug delivery.
Materials and methods
Materials
Chitosan (molecular weight = 20 KDa; degree of deacetyla-
tion = 92.5%) was purchased from Aoxing Biochemical Co, 
Ltd (Zhejiang, China). VES was purchased from Yuancheng 
Technology Development Co, Ltd (Wuhan, China). PTX was 
obtained from Xi’an Helin Biological Engineering Co, Ltd 
(Xi’an, China). EDC (1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride) was obtained from Shanghai 
Medpep Co, Ltd (Shanghai, China). Coumarin-6, -2, and -4, 
6-trinitrobenzenesulfonic acid solution (TNBS), and pyrene 
were purchased from Sigma (St Louis, MO). All other chemi-
cals and reagents were of analytical grade, and used without 
further purification.
synthesis of cs-Ves copolymer
CS-VES copolymer was prepared by conjugating the car-
boxyl group of VES with the amino groups of chitosan in 
the presence of EDC. The chemical structure of CS-VES 
is shown in Figure 1. In brief, chitosan (200 mg) was dis-
solved in 20 mL of 1.25% acetic acid solution, and VES 
(600 mg) was dissolved in 25 mL absolute ethyl alcohol 
followed by the addition of a suitable amount of EDC. 
These were then mixed in a flask and heated to 70°C for 
5 hours under mechanical stirring. The mixture was allowed 
to cool to room temperature for another 24 hours to allow 
further reaction, and the product was dialyzed in ethyl 
alcohol using a dialysis membrane (molecular weight cutoff 
[MWCO] = 12 KDa; Spectrum Laboratories, Ft Lauder-
dale, FL) to remove hydrophobic remains, then dialyzed in 
distilled water to remove hydrophilic byproducts, followed 
by freeze drying.
The chemical structure of the conjugate was analyzed 
using proton nuclear magnetic resonance spectroscopy (1H-
NMR) in D2O/DCl (5:1, v/v) solution at 300 MHz, and the 
infrared (IR) spectrum was recorded (Figure 2). The degree of 
substitution of the amino groups of chitosan was determined 
by the TNBS method.31
Preparation of PTX- or coumarin-6-
loaded micelles
PTX-loaded micelles were prepared by the nanoprecipitation/
dispersion technique involving the probe-type ultrasonic 
method. Briefly, 15 mg CS-VES conjugate was dissolved in 
6 mL diluted acetic acid, PTX was dissolved in absolute ethyl 
alcohol, and then the drug solution was added dropwise to 
the CS-VES solution. The mixture was then stirred at room 
temperature for 12 hours to vaporize the nonaqueous solvent. 
The resulting solution was then sonicated four times using 
a probe-type sonifier (JY92-2D, Scientz, Ningbo, China) at 
200 W for 5 minutes with the pulse turned off for 2 seconds 
at intervals of 3 seconds. The sonication process was carried 
out in an ice-bath to keep the temperature low. After that, the 
micelle solution was centrifuged at 3500 rpm for 20 minutes 
CS-VES copolymer
CS-VES micelle
Hydrophobic drug
Chitosan
Self-assemble
Vitamin E succinate
Figure 1B Illustration of the self-assembled micelles formed by cs-Ves copolymer under aqueous conditions.
Abbreviation: cs-Ves, chitosan/vitamin e succinate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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to remove any unloaded drug. The micelles loaded with 
fluorescent coumarin-6 were prepared in the same way, except 
that coumarin-6 was added to the micelle solution instead 
of PTX. The supernatant micelles were filtered through a 
0.8 µm syringe filter to remove any impurities before being 
stored at 4°C.
characterization of PTX-loaded micelles
size and zeta potential
The size and size distribution of the micelles were measured 
by dynamic light scattering (Nicomp TM 380, Particle Sizing 
Systems Inc, Santa Barbara, CA). The zeta potential of the 
micelles was determined using a ZetaPlus zeta potential ana-
lyzer (Delsa440SX, Beckmann-Coulter Electronics, Krefeld, 
Germany). The micelles were diluted with deionized water 
before measurement.
Drug encapsulation efficiency
The PTX content entrapped in the micelles was measured by 
high performance liquid chromatography (HPLC)   (Shimadzu, 
Kyoto, Japan). A reverse-phase ODS Diamonsil™ C18 
(Dikma, Beijing, China) column (250 mm × 4.6 mm, 5 µm) 
was used. In brief, 1 mL of micellar solution was diluted 
with 25 mL of methyl alcohol and sonication was used 
to collapse the micelles and dissolve the drug. The solu-
tion was then injected to HPLC after filtering it through a 
0.45 µm syringe filter. The flow rate of the mobile phase, 
consisting of acetonitrile and deionized water (60:40, v/v), 
was 1 mL/min. The column effluent was examined at 227 nm 
with a ultraviolet-visible detector. The calibration curve 
was linear over the range 2.5–50 µg/mL, with a correlation 
coefficient of R2 = 0.9999. The encapsulation efficiency was 
calculated as the percentage ratio of the amount of PTX 
incorporated into micelles to the total feeding amount of 
PTX. The drug-loading percentage was defined as the ratio of 
the PTX content to the amount of drug-loaded micelles.
Transmission electron microscopy (TeM)
The morphology of the CS-VES micelles was examined 
by TEM (H-600, Hitachi, Tokyo, Japan). A drop of micelle 
solution was stained with 2% (w/v) phosphotungstic acid 
for 3 minutes on a copper grid, followed by visualization 
under TEM.
critical micelle concentration (cMc)
The CMC of the CS-VES micelles was estimated using a 
hydrophobic fluorescence probe, pyrene, as reported previ-
ously.32,33 For this, 100 µL pyrene solution (3 × 10−5 mol/L 
in ethanol) was added to test tubes, and micelle   solution 
ranging from 1 to 500 µg/mL was added to the tubes after 
evaporation of the ethanol. The solution was then equili-
brated for 12 hours at room temperature in darkness, and 
sonicated for 30 minutes. At an excitation wavelength at 
337 nm and emission wavelengths of 373 and 385 nm, the 
emission spectra were recorded in a spectrofluorometer 
(F-2500, Hitachi).
Physical status of PTX in the micelles
The X-ray powder diffraction patterns were recorded in a 
Japan D/Max 2500 PC X-ray diffractomer (Rigaku, Tokyo, 
Japan) using graphite monochromatized Cu Kα radiation in 
the range of 3°–50°(2θ) at 50 kV and 300 mA.
Differential scanning calorimetry (DSC) was carried out 
using a TA-60 WS instrument (Shimadzu) to examine the 
nature of PTX in the CS-VES micelles. Samples, including 
chitosan, PTX, blank excipient (CS-VES), lyophilized PTX-
micelles, and a physical mixture of PTX and blank excipient 
were sealed with pinhole-pierced covers and analyzed at a 
heating rate of 10°C/minute from 25°C to 280°C under a 
stream of dry nitrogen.
In vitro release study
An in vitro drug release study was carried out by dialysis 
using phosphate-buffered saline (PBS) (pH 7.4, containing 
2% w/v Cremophor EL®) as the release medium.   Cremophor 
EL was used as a solubilizer of the PTX in the buffer, 
and 1 mL Taxol solution or micelles with 0.25 mg PTX 
were sealed in dialysis tubes (MWCO = 14 KDa, Spec-
trum Laboratories) which were then immersed in 80 mL 
release medium. The tubes were placed in an incubator shaker 
at 100 rpm and 37°C. At selected intervals, 2 mL samples 
were withdrawn and replaced with the same volume of fresh 
medium. The amount of PTX released from the micelles was 
determined by HPLC, with the detector set at 227 nm.
cell culture
Cellular uptake of fluorescent micelles
MCF-7 (human breast carcinoma cell line) was provided 
by Kaiji Biotech Co, Ltd (Nanjing, China). The cells were 
incubated in RPMI (Roswell Park Memorial Institute)-
1640 medium containing 10% (v/v) fetal bovine serum and 
1% penicillin-streptomycin at 37°C, under 5% humidity and 
5% CO2. They were then plated over a cover slide on a six-
well plate at a density of 2 × 105 cells per well for 24 hours 
at 37°C. To describe the uptake of CS-VES micelles in 
MCF-7, coumarin-6 was encapsulated in the micelles as 
a probe to study the uptake, and images were recorded by 
confocal laser scanning microscopy. After the cells formed International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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a confluent monolayer, they were equilibrated with Hanks’ 
balanced salt solution for 1 hour and then incubated with the 
coumarin-6-loaded micelles or coumarin-6 solution on the 
shaker. The cells were washed with cold PBS, fixed with 
70% ethanol for 20 minutes, and then washed twice more 
with PBS. The nuclei were then stained with propidium 
iodine solution (50 µg/mL) for 30 minutes. The monolayer 
was then fixed on a glass slide with gum and examined 
under a laser confocal scanning microscope (TCS SP2/
AOBS, Leica, Heidelberg, Germany).
In vitro cytotoxicity
The cytotoxicity of CS-VES micelles (drug-loading ratio 
21.37%) was evaluated using MCF cells in comparison with 
a Taxol formulation. MCF-7 cells were seeded into a 96-well 
plate at a density of 2 × 103 cells per well and cultivated for 
12 hours at 37°C. The plate was then incubated with CS-VES 
micelles and Taxol at 1, 10, and 100 ng/mL and 1, 10, and 
100 µg/mL equivalent PTX concentration and the same 
amount of blank excipient for 24, 48, and 72 hours, respec-
tively. At selected intervals, 50 µL microtiter tetrazolium 
(MTT) (2 mg/mL) was added to each well and incubated 
for a further 4 hours. After that, 200 µL dimethylsulfoxide 
was added to each well to dissolve the MTT formazan. The 
absorbance at 570 nm was measured using a microplate 
reader (Model 500; BioRad, Hercules, CA). Each sample 
was analyzed in triplicate. The cell viability was defined by 
the following equation:
  Cell viability (%)    =×
OD
OD
s
control
100%,
where ODs was the optical density of the cells incubated with 
CS-VES micelles, and ODcontrol was the optical density of the 
cells treated only with culture medium. Half-maximal inhibi-
tory concentration (IC50), the drug concentration at which 
inhibition of 50% cell growth was obtained, was carried out 
by curve fitting of the cell viability data.
hemolysis test
Dog blood was used to test the hemolysis effect of CS-VES 
copolymer. In brief, 10 mL whole blood was obtained from a 
8 ppm 6420
Figure 2A Proton nuclear magnetic resonance spectra of chitosan/vitamin e succinate 
conjugate (in D2O/Dcl, 5:1 v/v).
Figure 2B Infrared spectrum of cs-Ves.
Abbreviation: cs-Ves, chitosan/vitamin e succinate.
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beagle dog. The fibrinogen was removed with tally after stirring. 
Then, 5 mL physiological saline was added to the fibrinogen-free 
blood sample, and the erythrocytes were collected after centrifu-
gation at 2500 rpm for 10 minutes. The pellets were then washed 
three times with physiological saline until the supernatant was 
not red. Finally, a suitable amount of physiological saline was 
added to the erythrocyte pellets to prepare a 2% erythrocyte 
standard dispersion. The CS-VES copolymer was dissolved 
in physiological saline at a concentration of 10 mg/mL. Then, 
0.125, 0.25, 0.5, 0.75, and 1 mL polymer solution, respectively, 
was added to the five tubes containing 2.5 mL erythrocyte 
  pellets. Physiological saline was then added to every tube to 
give a final volume of 5 mL. A negative control was prepared by 
mixing 2.5 mL physiological saline with 2.5 mL 2% erythrocyte 
dispersion, and the physiological saline was replaced by water 
to give a positive control. After blending, all the tubes were 
incubated at 37°C and observed every hour.
Results and discussion
synthesis and characterization of the  
cs-Ves copolymer
CS-VES copolymer was successfully synthesized using EDC 
as a reaction catalyst by conjugating VES to the CS backbone. 
A strong proton peak of VES (at 0.4–1.0 ppm) appeared along 
with the proton peak of succinyl methylene (at about 2.5 ppm, 
Figure 2A). The IR spectrum further confirmed the formation 
of CS-VES conjugate (as shown in Figure 2B). The reduced 
intensity of the primary amines (at 3424 cm−1) confirmed that 
the amino groups of chitosan were substituted by VES. The 
enhanced peak (at 1635 cm−1) of the acetyl group and the 
appearance of the C-N linkage at 1404 cm−1 further confirmed 
the CS-VES structure. The degree of substitution of amino 
groups, estimated by the TNBS method was 20.4%, indicating 
that the conjugate had been synthesized successfully.
Pyrene was used as a fluorescent probe to measure the 
CMC of the CS-VES copolymer. The CMC value was 
determined to be 12.6 µg/mL (Figure 3). The lower CMC 
value indicated that the CS-VES copolymer can easily form 
a core-shell structure in an aqueous environment and retain 
the micellar structure integrity under diluted conditions in 
vitro and in vivo.
Preparation and characterization  
of PTX-loaded micelles
size, zeta potential, drug loading, PTX content,  
and encapsulation efficiency
To prepare the anticancer PTX-loaded micelles, PTX solu-
tion was injected into the CS-VES solution under mechanical 
stirring followed by ultrasonication. As shown in Table 1, 
the size of the blank micelles was 252 nm, and the size of 
the PTX-micelles ranged from 326 to 380 nm. The hydrody-
namic diameter increased with the increase in drug loading, 
suggesting that when more drug was entrapped in the micel-
lar hydrophobic core, the micellar inner core volume was 
increased. The TEM image showed the size and morphology 
of the PTX-micelles (Figure 4), and the physical appearance 
of the PTX-micelles are shown in Figure 5. Clearly, the nano-
micelles were spherical in shape with a homogeneous size 
  distribution. The micellar solution was clear and colorless with 
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Figure  3  Variation  of  fluorescence  intensity  ratio  (I1/I3)  versus  logarithm  of 
chitosan/vitamin e succinate concentration.
Table 1 Particle size, zeta potential, and encapsulation efficiency of PTX-loaded nanomicelles
Micelles PTX:CS-VES 
(charge ratio)
Particle size 
(nm)
Polydispersion Zeta potentiala  
(mV)
EEb (%) DLc (%)
Blank micelles – 252.3 ± 6.0 0.459 ± 0.009 24.9 ± 1.2 – –
PTX-micelles 1:10 326.3 ± 3.5 0.475 ± 0.013 22.8 ± 3.3 81.82 ± 0.95   7.52 ± 0.08
PTX-micelles 1:5 365.6 ± 1.3 0.390 ± 0.011 19.1 ± 2.5 82.03 ± 0.77 14.09 ± 0.11
PTX-micelles 1:3 380.8 ± 0.9 0.357 ± 0.030 19.5 ± 1.7 81.12 ± 0.56 21.37 ± 0.17
Notes:  aMeasurement was performed in deionized water (ph 7);  bdrug encapsulation efficiency = (amount of drug loaded in the micelles/amount of drug added during 
fabrication) × 100; cdrug loading ratio = (amount of drug loaded in the micelles/the total amount of drug in the micelles and cs-Ves conjugate used in the process) × 100. 
Mean ± standard deviation, n = 3.
Abbreviations: CS-VES, chitosan/vitamin E succinate; DL, drug loading ratio; EE, encapsulation efficiency; PTX, paclitaxel.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 4 Transmission electron microscope image of paclitaxel-loaded micelles.
Figure 5 Physical appearance of paclitaxel-loaded nanoparticles.
a light blue opalescence. The encapsulation efficiency of the 
PTX-micelles was over 80%, showing that there was a good 
bioaffinity between PTX and the CS-VES nanocarrier.
The highest drug-loading content was about 20%, indicat-
ing that PTX can be effectively solubilized by the CS-VES 
nanomicelles. The zeta potential not only plays an important 
role in the physical stability of the nanosystem, but also 
affects its interaction with the cell membrane.34 The zeta 
potentials of the blank-micelles and PTX-micelles were all 
positive and almost identical (Table 1). In this way, PTX 
loading did not affect the surface charge of the micelles, 
proving that the positively charged nanomicelle system inter-
acted well and there was strong adhesion to the negatively 
charged cell membrane.
Physical status of PTX in the cs-Ves nanomicelles
X-ray powder diffraction was used to characterize the physi-
cal existing status of PTX in the nanomicelles. As shown in 
Figure 6, diffraction peaks of PTX powder appeared from 
5°–25°, and these were also observed in the pattern of the 
physical mixture of PTX and blank micelles, but not in the 
pattern of PTX-loaded micelles.
DSC analyses of blank micelles, PTX-micelles, PTX, 
chitosan, and the physical mixture of PTX and blank micelles, 
were also conducted to further identify the physical status 
of PTX in the nanomicelles. The melting peak of pure PTX 
powder was about 213°C, which also appeared in the curve 
of the physical mixture (Figure 7). However, no melting peak 
of PTX was observed in the diagram of the PTX-loaded 
nanomicelles.
The above results indicate that PTX was encapsulated into 
the nanomicelles in an amorphous form, and no crystal drug 
nanoparticles were present in the nanomicelles.
In vitro release study
Three drug loadings of PTX-micelles, 7.52%, 14.09%, and 
21.37%, and Taxol (6 mg/mL) were prepared to   investigate 
the release profiles of CS-VES micelles in vitro. PBS 
(pH 7.4) containing 2% w/v Cremophor EL, was used as 
a release medium to maintain sink condition. The release 
results are presented in Figure 8. The Taxol formulation 
exhibited a fast drug release behavior in the first 10 hours, 
and the cumulative percentage release percent reached about 
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Figure 6 X-ray diffraction of: A, paclitaxel; B, physical mixture of blank micelles 
and paclitaxel (5:1 [w/w]); c, paclitaxel-loaded micelles (drug loading =14%); and   
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Figure 7 Differential scanning calorimetry thermograms of: A, blank micelles; B, paclitaxel-loaded micelles (drug loading = 14%); c, physical mixture of blank micellar system 
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Figure 8 In vitro release profiles of paclitaxel (PTX) from chitosan/vitamin E succinate nanomicelles in pH 7.4 phosphate-buffered saline (containing 2% Cremophor   
eL®, w/v).
the erosion rate of the biodegradable polymeric micelles 
may control the release behavior of PTX during the later 
release stage.
In vitro cellular uptake
The cellular internalization behavior of CS-VES nanomicelles 
containing coumarin-6 on MCF-7 cells was examined by con-
focal laser scanning microscopy. In Figure 9, the fluorescence 
images of the coumarin-6 solution and coumarin-6 loaded 
micelles, following incubation in MCF-7 cells for 30 minutes, 
are shown in row 1 and row 2. The images in row 3 and row 
4 show similar processes, with the incubation time being 
80% in 12 hours. In contrast to Taxol, PTX-micelles showed 
a near zero-order sustained-release profile, and no apparent 
burst release was observed. Three different drug loadings of 
PTX-micelles all showed similar release profiles. The cumu-
lative release percentage of PTX-micelles was about 22.31% 
during the initial 48 hours, and 34.61% PTX was released 
from the PTX-micelles for up to 96 hours. The cumulative 
percentage release by 168 hours reached 51.06%, 50.88%, 
and 44.35%, respectively, for the three PTX-micelles. As 
seen from the structure and composition of the nanomicelles, 
the release of PTX from polymeric micelles was mainly 
due to diffusion during the early release stage; by contrast, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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2 hours. The left column shows that the images obtained from 
the fluorescein isothiocyanate (FITC) channel corresponded 
to the green fluorescence of coumarin-6. The middle column 
shows the images from the rhodamine B isothiocyanate 
(RITC) channel which displayed the red   fluorescence of 
nuclei stained with propidium iodide. The right column 
shows the merged images of the FITC and RITC channels. 
As seen from rows 1 and 2, the fluorescence intensity of 
the coumarin-6 loaded micelles was significantly stronger 
than that of coumarin-6 solution, indicating that CS-VES 
nanomicelles were more efficiently taken up into the cancer 
cells. This might be due to the positive surface charge and 
appropriate particle size of the nanomicelles. When the incu-
bation period reached 2 hours, a similar trend was observed 
in rows 3 and 4, and the fluorescence intensity of coumarin-6 
loaded micelles was greater than that of coumarin-6 solution. 
 These results show that the cellular uptake of free courmarin-6, 
and courmarin-6-loaded CS-VES nanomicelles were   
Coumarin-6P I Merged
Figure 9 Confocal laser scanning microscopic images (in each column: left, fluorescein 
isothiocyanate channel; middle, rhodamine B isothiocyanate channel; right, merged 
images)  of  McF-7  cells  after  30  minutes’  incubation  with  coumarin-6  solution   
(row 1), coumarin-6-loaded micelles (row 2). rows 3 and 4 show formulations 
similar to those in rows 1 and 2, but incubation time was 2 hours.
Abbreviation: PI, propidium iodide.
time-dependent and the nanomicelles could be effectively 
endocytosed by MCF-7 cells. Similar findings have been 
reported previously.35 In addition, the fluorescence of CS-VES 
nanomicelles was much stronger in the cytoplasm than that at 
0.5 hours, and the fluorescence became uniformly dispersed 
in the nuclei after incubation for 2 hours.
In vitro cytotoxicity
To evaluate the cytotoxicity of PTX formulated in CS-VES 
nanomicelles and Taxol, MTT assay was carried out to com-
pare the cell viability after a 24-, 48-, and 72-hour incuba-
tion with MCF-7 cells at 37°C, and the results are shown in 
  Figure 10A. Generally, the cytotoxicity of the drug formu-
lated in the Taxol and CS-VES nanomicelles increased along 
with the increase in the drug concentration and incubation 
time. It would be expected that a higher drug concentration 
and longer incubation time would allow more drug to enter 
into cells. After the 24-hour incubation, the cell viability of 
the Taxol formulation of 1, 10, and 100 ng/mL and a drug con-
centration of 1, 10, and 100 µg/mL was found to be 91.92%, 
83.79%, and 71.72%, and 60.07%, 47.74%, and 13.22%, 
respectively. The cell viability after the 48-hour incubation for 
the Taxol formulation was 89.21%, 61.19%, 58.86%, 54.42%, 
45.15%, and 2.82%, and this decreased to 63.24%, 37.33%, 
and 33.36%, and 30.53%, 22.74%, and 2.18%, respectively, 
after 72 hours. Generally, the PTX-micelles exhibited a com-
parable but delayed cytotoxic effect compared with Taxol. 
The MCF-7 cell viability after a 24-hour incubation at drug 
concentrations of 1, 10, 100 ng/mL and 1, 10, 100 µg/mL 
was about 88.46%, 80.64%, 75.18%, 69.78%, 63.85%, and 
47.43%, and this reached 99.83%, 79.83%, 68.84%, 65.42%, 
52.79%, and 23.58% after 48 hours. After 72 hours treatment, 
the cell viability was further decreased to 74.72%, 53.54%, 
43.24%, 37.15%, 26.41%, and 3.16%, respectively. The 
delayed cytotoxicity of the polymeric micelle systems was 
probably due to their sustained-release characteristics, and 
PTX required more time to be released into the cytoplasm, 
as suggested in   Figure 11. The cytotoxicity of CS-VES 
copolymer was further compared with Cremophor EL. The 
results were shown in Figure 10B. Blank micelles showed 
obvious cytotoxicity, but a much stronger cytotoxcity was 
observed when the cells were incubated in the presence of 
Cremophor EL.
More importantly, one novel finding was that the blank CS-
VES nanomicelles were significantly cytotoxic to MCF-7 cells 
and could act as an anticancer efficacy enhancer for cytotoxic 
anticancer drugs. The cytotoxic effect of CS-VES copolymer 
was probably due to the apoptosis of VES, as reported in International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 10 (A) cytotoxicity of cs-Ves copolymer compared with cremophor eL®. (B) Diagrams of cell viability cultured with PTX-loaded cs-Ves micelles (PTX micelles) 
in comparison with Taxol® at the same dose and blank micelles at the same amount of copolymer. 
Note: Data shown mean ± standard error (n = 3).
Abbreviations: cs-Ves, chitosan/vitamin e succinate; PTX, paclitaxel.
MCF-7 cell
PTX
CS-VES copolymer
PTX-micelle
AB
Figure 11 schematic to explain the different cytotoxic effects of PTX solution 
and nanomicelles on an McF-7 cell. (A) The rapid inhibition effect of PTX solution 
by diffusion. (B) The delayed cytotoxicity of PTX-nanomicelles by endocytosis and 
sustained-release profile.
Abbreviations: cs-Ves, chitosan/vitamin e succinate; PTX, paclitaxel.
Table 2 Ic50 values in McF-7 cells after 24-, 48-, and 72-hour 
incubation with PTX formulated in Taxol® (Bristol-Myers squibb, 
New York, NY) and cs-Ves micelles
Incubation 
time (hours)
IC50 (μg/mL)
Taxol Blank micelles PTX-micelles
24 2.104 378.774 110.811
48 0.687 17.568 4.387
72 0.0662 4.710 0.152
Abbreviations: cs-Ves, chitosan/vitamin e succinate; Ic50, half-maximal inhibitory 
concentration; PTX, paclitaxel.
previous studies.27–30 The IC50 value was calculated using 
the cytotoxicity in MCF-7 cells after a 24, 48, and 72-hour 
incubation with Taxol and PTX-micelles (Table 2). The IC50 
value after 24, 48, and 72 hours treatment were 2.104, 0.687, 
and 0.0662 µg/mL for the Taxol formulation, 110.811, 4.387, 
and 0.152 µg/mL for PTX-micelles, and 378.774, 17.568, and 
4.710 µg/mL for the blank micelles, respectively.
hemolysis test
Since the supramolecular micellar aggregates are usually 
taken up by the intravenous route, a hemocompatibility test 
is needed to clarify the hemolysis of the novel CS-VES copo-
lymer. The erythrocyte pellets in the samples with CS-VES 
copolymer were easily dispersed after stirring, and no aggre-
gates were observed. There was no obvious difference between 
of the CS-VES copolymer compared with the negative control, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 12 The results of hemolysis test of the novel chitosan/vitamin e succinate 
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as shown in Figure 12. Also, complete hemolysis was observed 
in the samples of positive control, and the solution was clearly 
faintly red. These results show that the CS-VES copolymer 
did not produce any hemolysis and erythrocyte agglutination 
at the highest concentration of 2 mg/mL at 37°C, and so it is 
a safe nanocarrier for tumor-targeting drug delivery.
Conclusion
In this study, a novel self-assembled chitosan conjugate 
was synthesized with VES as the hydrophobic core for 
a water-insoluble anticancer drug reservoir and chitosan 
as the hydrophilic shell for bioadhesion. The new-type of 
CS-VES nanomicelles showed many fascinating features 
in terms of size, size distribution, zeta potential, high drug 
encapsulation efficiency, and sustained-release profile. 
The cellular uptake experiment demonstrated enhanced 
cellular uptake efficiency of PTX-micelles compared with 
the Taxol   formulation. Owing to the introduction of VES 
into the nanocarrier and the enhanced endocytosis mecha-
nism, PTX-loaded nanomicelles and even blank micelles 
exhibited significant cytotoxicity against MCF-7 cells. The 
hemolysis test showed that the CS-VES copolymer had a 
favorable safety profile. All of these results show that CS-
VES supramolecular micellar nanoaggregates have a prom-
ising future as nanocarriers for the delivery of anticancer   
drugs.
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